These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34878208)

  • 1. Successful perioperative prophylaxis with susoctocog alfa in a patient with acquired haemophilia A: A case study.
    Buczma A; Baran B; Korwin M; Odnoczko E; Windyga J
    Haemophilia; 2022 Mar; 28(2):e39-e41. PubMed ID: 34878208
    [No Abstract]   [Full Text] [Related]  

  • 2. Susoctocog Alfa: A Review in Acquired Haemophilia A.
    Burness CB; Scott LJ
    Drugs; 2016 May; 76(7):815-21. PubMed ID: 27098420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.
    Ozelo M; Misgav M; Abdul Karim F; Lentz SR; Martin-Salces M; Matytsina I; Saugstrup T; Santagostino E
    Haemophilia; 2015 Sep; 21(5):e436-9. PubMed ID: 26058730
    [No Abstract]   [Full Text] [Related]  

  • 4. Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.
    Lentz SR; Cerqueira M; Janic D; Kempton C; Matytsina I; Misgav M; Oldenburg J; Ozelo M; Recht M; Rosholm A; Savic A; Suzuki T; Tiede A; Santagostino E
    Haemophilia; 2016 Sep; 22(5):e445-9. PubMed ID: 27291066
    [No Abstract]   [Full Text] [Related]  

  • 5. Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A.
    Frampton JE; Wagstaff AJ
    Drugs; 2008; 68(6):839-53. PubMed ID: 18416588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporarily successful eradication therapy in acquired haemophilia with high inhibitor titer: a case report with a new protocol.
    Ilonczai P; Schlammadinger A; Oláh Z; Rázsó K; Bereczky Z; Boda Z
    Thromb Haemost; 2008 Jul; 100(1):149-50. PubMed ID: 18612550
    [No Abstract]   [Full Text] [Related]  

  • 9. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
    Tarantino M; Aledort L
    Transfusion; 2001 Dec; 41(12):1628-9. PubMed ID: 11778084
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis.
    Carcao M; Lambert T; Leissinger C; Escuriola-Ettingshausen C; Santagostino E; Aledort L;
    Haemophilia; 2018 Nov; 24(6):845-848. PubMed ID: 29989273
    [No Abstract]   [Full Text] [Related]  

  • 11. Two years' experience with two recombinant factor VIII concentrates.
    Brackmann HH; Aygören E; Scharrer I; Schwaab R; Hammerstein U; Oldenburg J
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):421-4. PubMed ID: 8329567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis in adult patients with severe haemophilia A.
    Oldenburg J; Brackmann HH
    Thromb Res; 2014 Nov; 134 Suppl 1():S33-7. PubMed ID: 25263019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lonoctocog Alfa: A Review in Haemophilia A.
    Al-Salama ZT; Scott LJ
    Drugs; 2017 Oct; 77(15):1677-1686. PubMed ID: 28900904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacokinetic model for factor VIII dosing during active haemorrhage in patients with haemophilia A.
    Ho AM; Dion P; Karmakar MK; Cheng G; Derrick JL; Chung DC; Tay BA
    Anaesthesia; 2001 Aug; 56(8):785-90. PubMed ID: 11493246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary prophylaxis in an adult patient with severe haemophilia A. Factor VIII consumption and effectiveness.
    Schlenkrich S; Schubert C
    Hamostaseologie; 2013 Aug; 33(3):241-4. PubMed ID: 23435748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
    Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
    Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with prophylaxis in Germany.
    Schramm W
    Semin Hematol; 1993 Jul; 30(3 Suppl 2):12-5. PubMed ID: 8367737
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.